Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction
Babula JJ, Bui D, Stevenson HL, et al. (2024). Diabetes, Obesity and Metabolism.
Summary
The most direct animal evidence for the compound itself, referred to here as 5A1MQ. Mice made obese on a high-fat diet received it daily for 28 days. The authors report that it limited gains in body weight and fat mass in a dose-dependent way, improved oral glucose tolerance and insulin sensitivity, suppressed raised insulin levels, and reduced fatty-liver changes on histology. The study also establishes how the compound behaves in the body after intravenous, oral and subcutaneous administration. Mice only; no human data exists for this compound.